title: Localized sources maintaining atrial fibrillation organized by prior ablation.
abstract: BACKGROUND
  Endocardial mapping of localized sources driving atrial fibrillation (AF) in humans has not been reported.
  
  
  RESULTS
  Fifty patients with AF organized by prior pulmonary vein and linear ablation were studied. AF was considered organized if mapping during AF showed irregular but discrete atrial complexes exhibiting consistent activation sequences for >75% of the time using a 20-pole catheter with 5 radiating spines covering 3.5-cm diameter or sequential conventional mapping. A site or region centrifugally activating the remaining atrial tissue defined a source. During AF with a cycle length of 211+/-32 ms, activation mapping identified 1 to 3 sources at the origin of atrial wavefronts in 38 patients (76%) predominantly in the left atrium, including the coronary sinus region. Electrograms at the earliest area varied from discrete centrifugal activation to an activity spanning 75% to 100% of the cycle length in 42% of cases, the latter indicating complex local conduction or a reentrant circuit. A gradient of cycle length (>20 ms) to the surrounding atrium was observed in 28%. Local radiofrequency ablation prolonged AF cycle length by 28+/-22 ms and either terminated AF or changed activation sequence to another organized rhythm. In 4 patients, the driving source was isolated, surrounded by the atrium in sinus rhythm, and still firing at high frequency (228+/-31 ms) either permanently or in bursts.
  
  
  CONCLUSIONS
  AF associated with consistent atrial activation sequences after prior ablation emanates mostly from localized sources that can be mapped and ablated. Some sources harbor electrograms suggesting the presence of localized reentry.
authors.affiliation: Hôpital Cardiologique du Haut-Lévêque, University Victor Segalen, Bordeaux, France. jacques.clementy@pu.u-bordeaux2.fr
authors.forename: Michel
authors.initials: M
authors.lastname: Haïssaguerre
authors.forename: Mélèze
authors.initials: M
authors.lastname: Hocini
authors.forename: Prashanthan
authors.initials: P
authors.lastname: Sanders
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Martin
authors.initials: M
authors.lastname: Rotter
authors.forename: Frederic
authors.initials: F
authors.lastname: Sacher
authors.forename: Thomas
authors.initials: T
authors.lastname: Rostock
authors.forename: Li-Fern
authors.initials: LF
authors.lastname: Hsu
authors.forename: Anders
authors.initials: A
authors.lastname: Jonsson
authors.forename: Mark D
authors.initials: MD
authors.lastname: O'Neill
authors.forename: Pierre
authors.initials: P
authors.lastname: Bordachar
authors.forename: Sylvain
authors.initials: S
authors.lastname: Reuter
authors.forename: Raymond
authors.initials: R
authors.lastname: Roudaut
authors.forename: Jacques
authors.initials: J
authors.lastname: Clémenty
authors.forename: Pierre
authors.initials: P
authors.lastname: Jaïs
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000494:pharmacology; D001145:Arrhythmias, Cardiac / Q000503:physiopathology / Q000628:therapy; D001281:Atrial Fibrillation / Q000503:physiopathology* / Q000628:therapy*; D018780:Body Surface Potential Mapping; D017115:Catheter Ablation; D002404:Catheterization; D004562:Electrocardiography; D004594:Electrophysiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011667:Pulmonary Veins
chemical_list: D000638:Amiodarone